Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;64(4):1923-1929.
doi: 10.1093/rheumatology/keae362.

The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus

Katie Liao  1 , Ning Li  2 , Julie Bonin  2 , Rachel Koelmeyer  2 , Joanna Kent  3 , Rebecca Pellicano  3 , Thilinie De Silva  1 , Kristy Yap  1 , Vera Golder  1   2 , A Richard Kitching  1   2 , Eric F Morand  1   2 , Alberta Hoi  1   2
Affiliations

The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus

Katie Liao et al. Rheumatology (Oxford). .

Abstract

Objectives: Anti-Ro60 and anti-Ro52 autoantibodies are frequently used as diagnostic biomarkers for Sjögren's disease, but their clinical significance in systemic lupus erythematosus (SLE) is not well characterized.

Methods: Patients fulfilling SLE classification criteria were studied according to their anti-Ro status. We defined Ro positivity (Ro+) as those who have either anti-Ro60 or anti-Ro52 positivity. Patient characteristics and disease outcomes, including High Disease Activity Status (HDAS) defined as an ever attainment of SLEDAI2K ≥10, adjusted mean SLEDAI (AMS), and time-adjusted mean clinical SLEDAI (excluding serologic activities) were compared using linear or logistic regressions. Furthermore, isolated or dual positivity of anti-Ro60 and anti-Ro52 were studied.

Results: Out of 409 patients, 47.2% were Ro+. Ro+ patients were predominantly Asian, had positive dsDNA and hypocomplementemia. They showed a higher likelihood of HDAS (OR 1.65, 95% CI 1.10-2.48, P = 0.015), AMS >4 (OR 1.84, 1.18-2.88, P = 0.007) and more frequent use of glucocorticoids (OR 1.87, 1.16-3.03, P = 0.011) and immunosuppressants (OR 2.0, 1.26-3.17, P = 0.003). Additionally, 24.4% of Ro+ patients experienced sicca symptoms, and hypergammaglobulinemia was significantly more common. Multivariate analysis confirmed that Asian ethnicity, severe flares, AMS, hypocomplementemia, rheumatoid factor, proteinuria, leucopenia and sicca symptoms were significantly linked to Ro positivity.

Conclusion: Anti-Ro positivity is associated with higher disease activity and increased treatment needs. Ro positivity correlates with laboratory abnormalities such as hypocomplementemia and leucopenia. These findings highlight the importance of anti-Ro60/Ro52 testing in the clinical evaluation of SLE.

Keywords: Ro positivity; Sjögren; overlap syndrome; prognostic marker; systemic lupus erythematosus.

PubMed Disclaimer

References

    1. Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y.. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol 2012;2012:606195. - PMC - PubMed
    1. Vitali C, Bombardieri S, Jonsson R. et al.; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8. - PMC - PubMed
    1. Mond CB, Peterson MG, Rothfield NF.. Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum 1989;32:202–4. - PubMed
    1. Fukuda MV, Lo SC, de Almeida CS, Shinjo SK.. Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus. Clin Rheumatol 2009;28:301–4. - PubMed
    1. Yao Q, Altman RD, Wang X.. Systemic lupus erythematosus with Sjogren syndrome compared to systemic lupus erythematosus alone: a meta-analysis. J Clin Rheumatol 2012;18:28–32. - PubMed